PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
22.25%
Revenue growth above 1.5x TSM's 11.40%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
30.11%
Gross profit growth above 1.5x TSM's 14.26%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
114.75%
EBIT growth above 1.5x TSM's 17.39%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
114.75%
Operating income growth above 1.5x TSM's 17.39%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
114.79%
Net income growth above 1.5x TSM's 16.30%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
116.00%
EPS growth above 1.5x TSM's 16.41%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
112.00%
Diluted EPS growth above 1.5x TSM's 16.41%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.32%
Share change of 0.32% while TSM is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
0.64%
Diluted share change of 0.64% while TSM is zero. Bruce Berkowitz might see a minor difference that could widen over time.
-0.32%
Dividend reduction while TSM stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-18.38%
Negative OCF growth while TSM is at 70.03%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-40.30%
Negative FCF growth while TSM is at 668.46%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
423.15%
10Y revenue/share CAGR 1.25-1.5x TSM's 289.09%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
217.61%
5Y revenue/share CAGR above 1.5x TSM's 59.19%. David Dodd would look for consistent product or market expansions fueling outperformance.
74.94%
3Y revenue/share CAGR 1.25-1.5x TSM's 59.24%. Bruce Berkowitz might see better product or regional expansions than the competitor.
463.12%
10Y OCF/share CAGR in line with TSM's 476.92%. Walter Schloss would see both as similarly efficient over the decade.
339.89%
5Y OCF/share CAGR above 1.5x TSM's 152.12%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
7.86%
3Y OCF/share CAGR under 50% of TSM's 238.75%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
1370.70%
Net income/share CAGR above 1.5x TSM's 413.78% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
376.30%
5Y net income/share CAGR above 1.5x TSM's 61.49%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
55.56%
3Y net income/share CAGR 50-75% of TSM's 75.43%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
394.32%
10Y equity/share CAGR above 1.5x TSM's 246.58%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
201.19%
5Y equity/share CAGR above 1.5x TSM's 61.80%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
135.54%
3Y equity/share CAGR above 1.5x TSM's 31.80%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
63.82%
Stable or rising mid-term dividends while TSM is cutting. John Neff sees an edge in consistent payouts vs. the competitor.
15.00%
Our short-term dividend growth is positive while TSM cut theirs. John Neff views it as a comparative advantage in shareholder returns.
22.17%
AR growth well above TSM's 5.00%. Michael Burry fears inflated revenue or higher default risk in the near future.
6.71%
Inventory growth well above TSM's 6.92%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
6.76%
Asset growth at 75-90% of TSM's 7.75%. Bill Ackman suggests reviewing opportunities to match or surpass the competitor's asset expansion if profitable.
9.85%
BV/share growth above 1.5x TSM's 4.86%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-1.69%
We’re deleveraging while TSM stands at 5.06%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
5.02%
We increase R&D while TSM cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-17.86%
We cut SG&A while TSM invests at 11.05%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.